Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Scheibenbogen

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Journal of Immunological Methods|April 9, 2001
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cellsA M Asemissen, D Nagorsen, U Keilholz, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2003
Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patientsA Schmittel, T Proebstle, R Engenhart-Cabillic, et al.
Melanoma Research|April 1, 1995
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapyT Möhler, M Willhauck, C Scheibenbogen, et al.
Cancer Immunology, Immunotherapy : CII|February 1, 1994
Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alphaR Landmann, U Keilholz, C Scheibenbogen, et al.
Journal of Immunological Methods|October 16, 1996
A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptidesS Mayer, C Scheibenbogen, K H Lee, et al.
Journal of Leukocyte Biology|June 1, 1990
Surface phenotype analysis of human monocyte to macrophage maturationR Andreesen, W Brugger, C Scheibenbogen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 4, 2000
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanomaC Scheibenbogen, A Schmittel, U Keilholz, et al.
Melanoma Research|August 1, 1995
Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effectsU Keilholz, C Scheibenbogen, T Möhler, et al.
Melanoma Research|August 1, 1997
UV-induced N-ras mutations are T-cell targets in human melanomaA van Elsas, C Scheibenbogen, C van der Minne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patientsC Scheibenbogen, K H Lee, S Mayer, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Journal of Immunological Methods|April 9, 2001
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cellsA M Asemissen, D Nagorsen, U Keilholz, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2003
Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patientsA Schmittel, T Proebstle, R Engenhart-Cabillic, et al.
Melanoma Research|April 1, 1995
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapyT Möhler, M Willhauck, C Scheibenbogen, et al.
Cancer Immunology, Immunotherapy : CII|February 1, 1994
Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alphaR Landmann, U Keilholz, C Scheibenbogen, et al.
Journal of Immunological Methods|October 16, 1996
A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptidesS Mayer, C Scheibenbogen, K H Lee, et al.
Journal of Leukocyte Biology|June 1, 1990
Surface phenotype analysis of human monocyte to macrophage maturationR Andreesen, W Brugger, C Scheibenbogen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 4, 2000
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanomaC Scheibenbogen, A Schmittel, U Keilholz, et al.
Melanoma Research|August 1, 1995
Addition of dacarbazine or cisplatin to interferon-alpha/interleukin-2 in metastatic melanoma: toxicity and immunological effectsU Keilholz, C Scheibenbogen, T Möhler, et al.
Melanoma Research|August 1, 1997
UV-induced N-ras mutations are T-cell targets in human melanomaA van Elsas, C Scheibenbogen, C van der Minne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patientsC Scheibenbogen, K H Lee, S Mayer, et al.
Pageof 7